Patents by Inventor Natalia Beglova

Natalia Beglova has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • COMPOSITIONS AND METHODS FOR TREATING ANTIPHOSPHOLIPID SYNDROME
    Publication number: 20150307581
    Abstract: The invention features compositions and methods of using a dimeric inhibitor, e.g., A1-A1, to selectively target ?2GPI in ?2GPI/antibody complexes. The compositions can be administered to subjects (e.g., a mammal, such as a human) having or likely to develop APS, or one or more symptoms of APS, in order to treat or inhibit the disease or treat or reduce its symptoms. The inhibitors of the invention include two ligand-binding A1 modules, e.g., from ApoER2, connected by a flexible linker.
    Type: Application
    Filed: February 20, 2015
    Publication date: October 29, 2015
    Inventor: Natalia BEGLOVA
  • Compositions and methods for treating antiphospholipid syndrome
    Patent number: 8993518
    Abstract: The invention features compositions and methods of using a dimeric inhibitor, e.g., A1-A1, to selectively target ?2GPI in ?2GPI/antibody complexes. The compositions can be administered to subjects (e.g., a mammal, such as a human) having or likely to develop APS, or one or more symptoms of APS, in order to treat or inhibit the disease or treat or reduce its symptoms. The inhibitors of the invention include two ligand-binding A1 modules, e.g., from ApoER2, connected by a flexible linker.
    Type: Grant
    Filed: October 31, 2011
    Date of Patent: March 31, 2015
    Assignee: Beth Israel Deaconess Medical Center, Inc.
    Inventor: Natalia Beglova
  • COMPOSITIONS AND METHODS FOR TREATING ANTIPHOSPHOLIPID SYNDROME
    Publication number: 20130252887
    Abstract: The invention features compositions and methods of using a dimeric inhibitor, e.g., A1-A1, to selectively target ?2GPI in ?2GPI/antibody complexes. The compositions can be administered to subjects (e.g., a mammal, such as a human) having or likely to develop APS, or one or more symptoms of APS, in order to treat or inhibit the disease or treat or reduce its symptoms. The inhibitors of the invention include two ligand-binding A1 modules, e.g., from ApoER2, connected by a flexible linker.
    Type: Application
    Filed: October 31, 2011
    Publication date: September 26, 2013
    Inventor: Natalia Beglova